On February 3, 2022 EVERSANA, the pioneer of next generation commercial services to the global life sciences industry, reported a strategic partnership with Integra Connect, LLC, designed to support life sciences companies as they develop and commercialize new oncology treatments (Press release, EVERSANA, FEB 3, 2022, View Source [SID1234607764]). EVERSANA and Integra Connect, the leading provider of value-based, precision medicine technologies and services for specialty care, will contribute market-leading expertise, real-world data and technologies to create a comprehensive longitudinal oncology patient database. Once available, life sciences companies will be able to leverage the database to optimize their decision-making across a product’s entire life cycle.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Currently, life sciences companies are working to make commercial decisions based on value-based, precision medicine principles but struggle to effectively gather and apply high-quality, real-world oncology data. This is because commercialization insights are limited by multisite care and a complex care ecosystem with disparate data assets. The EVERSANA and Integra Connect solution will give life sciences companies greater visibility into variables that may impact commercial success by combining real-world data (RWD) from sources such as electronic health records (EHRs) and expert analyses from EVERSANA’s value and evidence team. Together, these capabilities will help life sciences leaders to substantiate the product’s value across the commercialization ecosystem, including evidence development strategy, reimbursement submissions and payer marketing. The combined solution will be available on the Integra Connect’s value-based, precision medicine platform.

Specifically, to accelerate the development of new therapies and evidence-based commercialization, EVERSANA will leverage its internationally recognized HEOR and data science as well as Integra Connect’s platform to provide curated RWD and research support. The real-world data of the combined solutions will characterize baseline patient attributes, disease progression and treatment-based outcomes for patients; and will model customized commercialization models, including EVERSANA’s real-time patient services available from its patient service hub.

"Together with Integra Connect, we are transforming oncology commercialization services with the power of real-world data and evidence throughout the product and patient journeys," said Jim Lang, CEO, EVERSANA. "The combination of scaled clinical data, with expert curation, and a scaled HEOR and data science capability will give life sciences partners the ability to accelerate clinical programs and validate therapeutic impact for all stakeholders, especially patients and caregivers."

"The partnership is an important step in enabling life sciences companies to successfully bring forth oncology treatments that are beneficial to patients and viable in a value-based, precision medicine environment," said Charles Saunders, MD, CEO of Integra Connect. "Additionally, I am proud of Integra Connect’s continued leadership in creating new innovations and strategic partnerships that will help make value-based precision medicine a reality for patients, providers and populations."

On February 3, 2022 F. Hoffmann-La Roche Ltd. (hereafter "Roche") [Head Office: Basel, Switzerland. CEO: Severin Schwan] reported its financial results for fiscal 2021 (January 1 – December 31, 2021) (Press release, Chugai, FEB 3, 2022, View Source [SID1234607658]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Roche owns 59.89% of Chugai’s outstanding shares (61.16% of the total number of shares issued excluding treasury stock) as of the end of December 2021.

Its press release and presentation materials can be found on its website (View Source).
Chugai’s performance for the period of January 1 to December 31, 2021 is included in the announced Roche Group’s results.

On February 3, 2022 Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, reported the publication of a peer-reviewed article titled, "A Small Molecule–Drug Conjugate (SMDC) Consisting of a Modified Camptothecin Payload Linked to an αVß3 Binder for the Treatment of Multiple Cancer Types" in the special issue "The Role of Tumor Microenvironment in Solid Tumors: The New Frontier of Cancer Research" of the journal Cancers (Press release, Vincerx Pharma, FEB 3, 2022, View Source [SID1234607677]). The preclinical data in the paper highlight the potential of VIP236, a small molecule-drug conjugate (SMDC), to directly target cancer cells, while reducing the harmful effects of chemotherapy to normal tissue.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"These preclinical data provide compelling proof-of-concept that our novel SMDC, VIP236, can direct a potent cancer chemotherapy drug to tumors while sparing healthy tissues," said Ahmed Hamdy M.D., Chief Executive Officer of Vincerx. "We have a diverse, modular platform of linkers and payloads that can be conjugated with typical antibodies or small molecules, creating the potential for novel drugs with greater efficacy and lower toxicities than current antibody-drug conjugates; VIP236 is an example of the strength of this platform."

VIP236 tumor homing is guided by an αVß3 integrin ligand, which targets mechanisms that drive aggressive and invasive cancers. The published results provide preclinical validation of this targeting strategy and demonstrate how this approach can deliver 40 times more drug to the cancer than the surrounding tissues or normal organs. VIP236 is further activated by another component prevalent in the tumor microenvironment of invasive cancers, neutrophil elastase, which cleaves the linker, releasing a potent payload directly in the tumor microenvironment. The payload is a differentiated camptothecin (CPT) optimized to be more cell permeable and to overcome drug resistance observed with traditional CPTs.

Dr. Hamdy continued, "Our promising in vivo mouse data across various tumor types highlight the potential of our rationally designed SMDC to transform the treatment paradigm for advanced solid tumors. We look forward to advancing VIP236 into the clinic in the second half of 2022."

Key Article Highlights Include:

The αVß3 integrin targeting strategy in VIP236 increases tumor homing by 42-fold as measured by a fluorescent dye conjugated to the integrin targeting moiety and demonstrated in a human renal cell carcinoma (786-O) xenografted mouse model.
The cytotoxic payload of VIP236, VIP126, is an optimized CPT which shows improvement in permeability, efflux ratio and cytotoxicity in drug transporter overexpressing cancer cells compared with SN38, a clinically validated CPT. Unlike SN38, VIP126 is a very poor substrate for P-gp- or BCRP-mediated efflux transport, which translated into greater efficacy.
VIP236 in vitro cytotoxic activity against tumor cell lines is neutrophil elastase (NE) dependent.
Neutrophil elastase, prevalent in the tumor microenvironment, cleaves the linker, to release the anticancer payload within the tumor.
VIP236 results in a ten-fold higher tumor-to-plasma ratio of the payload, VIP126, when compared to direct administration of VIP126 in vivo, highlighting a potential therapeutic advantage of the conjugate delivery system.
Compared with commonly used chemotherapeutics, VIP236 shows very effective tumor targeting, better tumor regression, and better tolerability in mouse models of triple negative breast cancer, small cell lung cancer and colorectal cancer.

On February 3, 2022 Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, reported that management will participate in upcoming investor conferences (Press release, Zymeworks, FEB 3, 2022, View Source [SID1234607692]).

Guggenheim Oncology Conference 2022. Zymeworks will participate virtually in one-on-one meetings and a fireside chat on February 9th at 1:00 p.m. ET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

11th Annual SVB Leerink Global Healthcare Conference. Zymeworks will participate virtually in one-on-one meetings and a fireside chat on February 17th at 3:40 p.m. ET.

Fireside chats will be webcast live with dial-in details and webcast replays available on Zymeworks’ website at View Source

On February 3, 2022 Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, reported that members of its senior management team will participate in two virtual investor conferences in February (Press release, Repare Therapeutics, FEB 3, 2022, View Source [SID1234607712]). Details are as follows:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Guggenheim Oncology Conference
Date: Thursday, February 10, 2022
Time: 2:00 p.m. Eastern Time

11th Annual SVB Leerink Global Healthcare Conference
Date: Friday, February 18, 2022
Time: 3:00 p.m. Eastern Time

A live webcast of the Guggenheim Oncology Conference fireside chat will be available starting Thursday, February 10, 2022 at 2:00 p.m. Eastern Time in the Investor section of the Company’s website at View Source A replay of the webcast will be archived on the Company’s website for 90 days.

A live webcast of the 11th Annual SVB Leerink Global Healthcare Conference presentation will be available on Friday, February 18, 2022 at 3:00 p.m. Eastern Time in the Investor section of the Company’s website at View Source A replay of the webcast will be archived on the Company’s website for 90 days.